Drug
Erlotinib
Data on this page refer exclusively to patients treated with
Erlotinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
EGFR targeting TKI group page.
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | EGFR targeting TKI |
| Mechanism of Action | EGFR inhibitor |
| Half-life | 36 h |
Location
Treated site
